Top

Published in:

01-08-2013 | Cardiovascular Disease and Stroke (D Leifer and JE Safdieh, Section Editors)

Genetic Profiles in Ischaemic Stroke

Authors: Steve Bevan, Hugh S. Markus

Published in: Current Atherosclerosis Reports | Issue 8/2013

Abstract

Stroke represents a clinical syndrome rather than a single disease. A number of stroke subtypes can be distinguished based on careful phenotyping, with each of these having distinct and overlapping risk factor profiles. Recent evidence has suggested that genetics plays an important part in stroke risk, with at least 2 genes specific to stroke risk directly now having been identified. This review will explore our current understanding of the genetics underlying stroke risk and whether this information is currently useful in a clinical setting for patient benefit.

Roger V, Go A, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.PubMedCrossRef

Seshadri S, Beiser A, Kelly-Hayes M, Kase C, Au R, Kammel W, et al. The lifetime risk of stroke: estimates from the Framingham study. Stroke. 2006;37:345–50.PubMedCrossRef

Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72:368–74.PubMedCrossRef

Zhang J, Claterbuck RE. Molecular genetics of human intracranial aneurysms. Int J Stroke. 2008;3:272–87.PubMedCrossRef

Sacco R, Ellenberg J, Mohr J, Tatemichi T, Hier D, Price T, et al. Infarcts of undetermined cause: the NINDS stroke data bank. Ann Neurol. 1989;25:382–90.PubMedCrossRef

Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–10.PubMedCrossRef

Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000;123:1784–812.PubMedCrossRef

Flossmann E, Schulz U, Rothwell P. Systematic review of methods and results of studies of the genetic epidemiology of ischaemic stroke. Stroke. 2004;35:212–27.PubMedCrossRef

Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischaemic stroke subtypes - a family history study. Stroke. 2003;34:1364–9.PubMedCrossRef

10.

Duggirala R, Gonzalez Villalpando C, O'Leary DH, Stern MP, Blangero J. Genetic basis of variation in carotid artery wall thickness. Stroke. 1996;27(5):833–7.PubMedCrossRef

11.

Jartti L, Ronnemaa T, Kaprio J, Jarvisalo MJ, Toikka JO, Marniemi J, et al. Population-based twin study of the effects of migration from Finland to Sweeden on endothelial functrion and intima-media thickness. Arterioscler Thromb Vasc Biol. 2002;22(5):832–7.PubMedCrossRef

12.

Moskau S, Golla A, Grothe C, Boes M, Pohl C, Klockgether T. Heritability of carotid artery atherosclerotic lesions. Stroke. 2005;36:5–8.PubMedCrossRef

13.

Carmelli D, DeCarli C, Swan G, Jack L, Reed T, Wolf P, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177–81.PubMedCrossRef

14.

Atwood L, Wolf P, Heard-Costa N, Massaro J, Beiser A, D'Agostino R, et al. Genetic variation in white matter hyperintensity volume in the Framingham study. Stroke. 2004;35:1609–13.PubMedCrossRef

15.

Turner S, Fornage M, Jack C, Mosley T, Knopman D, Kardia S, et al. Genomic susceptibility loci for brain atrophy, ventricular volume and leukoaraiosis in hypertensive sibships. Arch Neurol. 2009;66:847–57.PubMedCrossRef

16.

Markus HS. Unravelling hte genetics if ischaemic stroke. PLoS Med. 2010;7:e1000225.PubMedCrossRef

17.

Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005;36:2027–31.PubMedCrossRef

18.

Martini SRFM, Brown WM, Haverbusch M, Comeau ME, Sauerbeck LR, Kissela BM, et al. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. Neurology. 2012;79:2275–82.PubMedCrossRef

19.

Edwards A, Ritter R, Abel K, Manning A, Panhuysen C, Farrer L. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–4.PubMedCrossRef

20.

Hardy J, Singleton A. Genomewide association studies and human disease. N Eng J Med. 2009;360:1759–68.CrossRef

21.

Schunkert H, Gotz A, Braund P, McGinnis R, Tregouet D-A, Mangino M, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation. 2008;117:1675–84.PubMedCrossRef

22.

Gudbjartsson D, Arnar D, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448(353):358.

23.

Gudbjartsson D, Holm H, Gretarsdottir S, Thorleifsson G, Walters G, Thorgeirsson G, et al. A sequence variant in ZFHX3 on 16q22 associates with arterial fibrillation and ischaemic stroke. Nat Genet. 2009;41:876–8.PubMedCrossRef

24.

Gschwendtner A, Bevan S, Cole J, Plourde A, Matarin M, Ross-Adams H, et al. Sequence variants on Chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol. 2009;65:531–9.PubMedCrossRef

25.

Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischaemic stroke. Ann Neurol. 2008;64:402–9.PubMedCrossRef

26.

Matarin M, Brown W, Scholz S, Simon-Sanchez J, Fung H-C, Hernandez D, et al. A genome wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 2007;6:414–20.PubMedCrossRef

27.

Ikram A, Seshadri S, Bis J, Fornage M, DeStefano A, Aulchenko Y, et al. Genomewide association studies of stroke. N Eng J Med. 2009;360:1718–28.CrossRef

28.

International Stroke Genetic Consortium and Wellcome Trust Case Control Consortium 2. Failure to validate association between 12p13 variants and ischaemic stroke. N Eng J Med. 2010;362:1547–50.CrossRef

29.

•• Bellenguez C, Bevan S, Gschwendtnew A, Spencer C, Burgess AI, Pirinen M, et al. Genetic analysis identifies a new susceptibility locus in HDAC9 for large vessel ischemic stroke, and supports genetic heterogeneity across stroke subtypes. Nat Genet. 2012;44:328–33. First use of GWAS to identify genetic predisposition to ischaemic stroke showing successful and robust replication.PubMedCrossRef

30.

Markus HS, Makela K-M, Bevan S, Raitoharju E, Oksala N, Bis JC, et al. Evidence HDAC9 genetic variant associated with ischaemic stroke increases risk via promoting carotid atherosclerosis. Stroke 2013;In Press.

31.

Bowes AJ, Khan MI, Shi Y, Robertson L, Werstuck GH. Valproate attenuates accelerated atherosclerosis in hyperglycemic ApoE deficient mice: Evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic stenosis. Am J Pathol. 2009;174:330–42.PubMedCrossRef

32.

Olesen JB, Abildstrom SZ, Erdal J, Gislason GH, Weeke P, Andersson C, et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke and death in patients with or withour previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf. 2011;20:964–71.PubMedCrossRef

33.

• Holliday EG, Maguire J, Evans T-J, Koblar S, Jannes J, Sturm J, et al. Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet. 2012. doi:10.1038/ng.2397. Second GWAS based gene identification specific to ischaemic stroke with robust replication.

34.

•• Traylor M, Farrall M, Holliday E, Sudlow C, Hopewell J, Cheng Y-C, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–62. Largest and most powered genetic meta-analysis of GWAS based stroke studies published to date.PubMedCrossRef

35.

Williams FMK, Carter AM, Hysi PG, Surdulescu G, Hodgkiss D, Soranzo N, et al. Ischaemic stroke is associated with the ABO locus: The EuroCLOT study. Ann Neurol. 2012;73:16–31.CrossRef

36.

Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex disease. Nature. 2009;461:747–53.PubMedCrossRef

37.

Yang J, Lee S, Goddard M, Visscher P. GCTA: a tool for genome wide complex trait analysis. Am J Hum Genet. 2011;88:76–82.PubMedCrossRef

38.

Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NLM, Jackson C, et al. Genetic heritability of ischaemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43:3161–7.PubMedCrossRef

39.

Metzker M. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11:31–46.PubMedCrossRef

40.

Lin B, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE published literature database. Am J Epidemiol. 2006;164:1–4.PubMedCrossRef

41.

Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Eng J Med. 2011;364:1144–53.CrossRef

42.

Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. BJCP. 2013. doi:10.1111/j.1365-2125.2008.03183.x.

43.

Neubauer H, Kaiser A, Endres H, Kruger J, Engelhardt A, Lask S, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011. doi:10.1186/1741-7015-9-3:3.PubMed

44.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39.CrossRef

45.

Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875–84.PubMedCrossRef

46.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Eng J Med. 2009;360:354–62.CrossRef

47.

Sibbing D, Bernlochner I, Kastrati A, Pare G, Eikelboom JW. Current evidence for genetic testing in clopidogrel treated patients undergoing coronary stenting. Circ Cardiovasc Interv. 2011;4:505–13.PubMedCrossRef

48.

Pare G, Eikelboom JW, Sibbing D, Bernlochner I, Kastrati A. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2011;4:514–21.PubMedCrossRef

49.

Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–9.PubMedCrossRef

50.

Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics. 2010;11:493–6.PubMedCrossRef

51.

Ja J, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–9.CrossRef

Title: Genetic Profiles in Ischaemic Stroke
Authors: Steve Bevan
Hugh S. Markus
Publication date: 01-08-2013
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 8/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-013-0342-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2013

Novel Oral Anticoagulants for Atrial Fibrillation

Treatment of Symptomatic Carotid Stenosis: Carotid Stent Placement Versus Endarterectomy

A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials

Systematic Review of Telestroke for Post-Stroke Care and Rehabilitation

The Effect of Statins on Skeletal Muscle Function: The STOMP Trial

Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials